GSK Just Sold Its Itch Drug Two Weeks Before the FDA Decision
GSK sold its severe itch drug linerixibat to Alfasigma for $300 million, just two weeks before an FDA decision. The deal reveals how Big Pharma is shedding promising niche assets to chase bigger markets.
Imagine spending years developing a drug, shepherding it through clinical trials, filing for FDA approval, and then selling it to someone else two weeks before the finish line. That's exactly what GSK just did.
The British pharma giant handed over worldwide rights to linerixibat, a treatment for severe, relentless itching caused by a rare liver disease, to Italian pharmaceutical company Alfasigma for $300 million upfront. The FDA's decision date? March 24, 2026. That's not months away. That's days.
So why would GSK bail right before the payoff?
A Drug for an Itch You Can't Scratch
First, some context on what linerixibat actually does. It's designed for patients with primary biliary cholangitis (PBC), an autoimmune liver disease that affects bile ducts. One of the most maddening symptoms? Cholestatic pruritus: a deep, internal itching that up to 89% of PBC patients experience. We're not talking about a mosquito bite. This is itching that comes from inside your body, can't be relieved by scratching, and wrecks your sleep.
Linerixibat works by blocking something called the ileal bile acid transporter (IBAT), essentially a gatekeeper that recycles bile acids in your gut. In PBC patients, bile acids build up and trigger that unbearable itch. Block the transporter, reduce the buildup, calm the itch. Think of it like unclogging a drain so water stops flooding the bathroom floor.
The drug cleared its Phase 3 trial, called GLISTEN, hitting its primary endpoint with improvements in both itch severity and sleep disruption compared to placebo. It's currently under regulatory review in the U.S., EU, UK, China, and Canada, and it carries Orphan Drug status in the U.S., EU, and Japan.
Follow the Money
The deal structure tells a clear story about risk and reward. Alfasigma pays $300 million upfront just to get in the door. If the FDA says yes on March 24, GSK collects another $100 million. EU and UK approvals would trigger an additional $20 million. Sales milestones could add up to $270 million more, plus tiered double-digit royalties on worldwide net sales.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
